Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-01-31
2006-01-31
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S302000, C514S234200, C514S303000, C514S252110, C514S218000, C540S575000, C544S127000, C544S362000, C544S121000, C544S357000, C546S115000, C546S120000
Reexamination Certificate
active
06992086
ABSTRACT:
The present invention relates to chemical compounds, pharmaceutical compositions comprising said compounds, uses of said compounds and compositions, methods of treatment employing said compounds and compositions, and processes for preparing said compounds. Specifically, this invention relates to novel compounds which are antagonists of MCP-1 function and are useful in the prevention or treatment of chronic or acute inflammatory or autoimmune diseases, especially those associated with aberrant lymphocyte or monocyte accumulation such as arthritis, asthma, atherosclerosis, diabetic nephropathy, inflammatory bowel disease, Crohn's disease, multiple sclerosis, nephritis, pancreatitis, pulmonary fibrosis, psoriasis, restenosis, and transplant rejection. More specifically, the invention is related to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases.
REFERENCES:
patent: 3823144 (1974-07-01), Schmitt et al.
patent: 4269990 (1981-05-01), May et al.
patent: 5977108 (1999-11-01), Kikuchi et al.
patent: 6140338 (2000-10-01), Naya et al.
patent: 6228869 (2001-05-01), Levin et al.
patent: 6288103 (2001-09-01), Faull et al.
patent: 6316449 (2001-11-01), Bratton et al.
patent: 6329402 (2001-12-01), Kikuchi et al.
patent: 6342516 (2002-01-01), Umeda et al.
patent: 2 001 284 (1969-09-01), None
patent: 1 250 611 (1974-10-01), None
patent: 9-255572 (1997-09-01), None
patent: 92/14710 (1992-09-01), None
patent: 97/24325 (1997-07-01), None
patent: 97/44329 (1997-11-01), None
patent: 98/02151 (1998-01-01), None
patent: 98/06703 (1998-02-01), None
patent: 98/27815 (1998-07-01), None
patent: 98/04554 (1999-05-01), None
patent: 99/40072 (1999-08-01), None
patent: 00/46198 (2000-08-01), None
patent: WO 01/36403 (2001-05-01), None
patent: 01/57003 (2001-08-01), None
patent: 01/57021 (2001-08-01), None
patent: 01/57044 (2001-08-01), None
patent: WO 02/060900 (2002-08-01), None
Alam et al., “Increased MCP-1, RANTES, and MIP-1α in Bronchoalveolar Lavage Fluid of Allergic Asthmatic Patients”,Am J Respir Crit Care Med, 153:1398-1404. (1996).
Alcami et al., “Blockade of Chemokine Activity by a Soluble Chemokine Binding Protein form Vaccinia Virus”,J Immunol, 160:624-633 (1998).
Antoniades et al., “Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis”,Proc Natl Acad Sci USA, 89:5371-5375 (1992).
Ajuebor et al., “Endogenous monocyte chemoattractant protein-1 recruits monocytes in the zymosan peritonitis model”,Journal of Leukocyte Biology, vol. 63:108-116, Jan. 1998.
Baggiolini et al., “Human Chemokines; an update”, Annu rev Immunol (1997), pp. 15:675-705.
Baggiolini, Chemokines and Leukocyte Traffic, Nature vol.: 392:9 pp 565-568, (1998).
Boring et al., “Decreased lesion formation in CCR2−/−mice reveals a role for chemokines in the initiation of atherosclerosis”,Nature, 394:894-897 (1998).
Bright et al., “Identification of a Non Peptidic Rantes Antagonist”,Bioorg Med Chem Lett, 8:771-774 (1998).
Campbell et al., “Monocyte Chemoattractant Protein-1 Mediates Cockroach Allergen-Induced Bronchial Hyperreactivity in Normal but Not CCR2−/−Mice: The Role of Mast Cells”,J Immunol, 163:2160-2167 (1999).
Chemical Abstracts, 103(17), Abst. No. 141873u (1985); Abstract of Kuxzinski, L. et al.: “Synthesis of new 4 and 5 disubstituted isothizoles ” Pol J Pharmacol Pahrm, 36(5):485-491 (1984).
Chemical Abstracts, 100(21), Abst. No. 174751u (1984):Abstract of Ormek, G. et al., “Ring-opening reactions of potentially biologically active benzothienooxazines” Arc Pharm, 317(2):117-120 (1984).
Folkman and Shing, “Control of Angiogensis by Heparin and Other Sulfated Polysaccharides”,Adv Exp Med Biol.,313:355-364 (1992).
Forbes et al., “CCR2B Receptor Antagonists: Conversion of a Week HTS Hit to a Potent Lead Compound”;Bioorg Med Chem. Lett, 10:1803-1806 (2000).
Gosling et al., “MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that over express human apo37lipoprotein B”,J Clin Invest, 103:773-778 (1999).
Gu et al., “Absence of Monocyte Chemoattractant Protein-1 Reduces Atherosclerosis in Low Density Lipoprotein Receptor-Deficient Mice”,Mol Cell, 2:275-281 (1998).
Hesselgesser, “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor”,J. Biol Chem, 273:15687-15692 (1998).
Hoogewerf et al., “Glycosaminoglycans Mediate Cell Surface Oligomerization of Chemokines”, Biochemistry 36:13570-13578, (1997).
Hosaka et al., “Expression of the Chemokine Superfamily in Rheumatoid Arthritis”,Clin Exp Immunol, 97:451-457. (1994).
Hsieh et al., “Immunotherapy Suppresses the Production of monocyte chemotatic and activating factor and augments the production of IL-8 in Children with Asthma”,J Allery Clin Immunol, 98:580-587 (1996).
Kitano M. et al., “Synthesis and Biological Activity of N-(Aminoiminomethly)-1H-Idoleca Rboxamide Inhibitors”, Chem and Pharm Bulletin, Pharmaceutical Society of Japan, vol. 47, No. 11, Nov. 1999, pp 1538.
Koch et al., “Enhanced Production of Monocyte Chemoattractant Protein-1 in Rheumatoid Arthritis”,J Clin Invest, 90:772-779, (1992).
Kunkel et al., “The Role of Chemokines in Inflammatory Joint Disease”,J Leukocyte Biol, 59:6-12 (1996).
Kurashima et al., “Increase of Chemokine Levels in Sputum Precedes Exacerbation of Acute Asthma Attacks”,J Leukocyte Biol, 59:313-316, (1996).
Kuschert et al., “Glycosamineoglycans interact selectively with chemokines and moldulate receptor binding and cellular responses”,Biochemistry38:12959-12968, (1999).
Liang et al., “Identification and characterization of a potent, selective and orally active antagonist of the cc chemokine receptor-1”,The Journal of Biological Chemistry, vol. 25:19000-19008, Jun. 23, 2000.
Luster, “Chemokines—Chemotactic Cytokines That Mediate Inflammation”,The New England Journal of Medicine, pp. 436-445, Feb. 12, 1998.
McFadden and Kelvin, “New Strategies for Chemokine Inhibition and Modulation”,Biochem Pharmacol, 54:1271-1280 (1997).
Mirzadegan et al., “Identification of the binding site for a novel class of CCR2bcemokine receptor antagonists . . . ”, The American Society for Biochemistry and Molecular Biology, Inc., manuscript M000692200, (2000).
Moore et al., “Tumor angiogenesis is regulated by CXC chemokines”,J Lab Clin Med, 132:97-103 (1998).
Moore et al., “CXC Chemokine Modulation of angiogenesis . . . ”, J Investigative Medicine, vol. 46:113-120 (1998).
Murphy, : The Molecular Biology of Leukocyte Chemoattractant Receptors,Annu Rev Immun, 12:593-633, (1994).
Nelken et al., “Monocyte Chemoattractant Protein-1 in Human Atheromatous Plaques”;J. Clin Invest, 88:1121-1127 (1991).
Okada et al., “Synthesis and Antitumor Activities of Water-Soluble Benzoylphenylureas”,Chem Pharm Bull, 47:430-433, (1999).
Okada et al., “Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas”,Chem Pharm Bull42:57-61, (1994).
Okada et al., “Synthesis and Antitumor Activities of Novel Benzoylphenylurea Derivatives”,Chem Pharm Bull, 39:2308-2315 (1991).
Proost et al., “The Role of Chemokines in Inflammation”,Int J Clin Lab Res, 26:211-223, (1996).
Robinson et al., “Chemokine expression in Rheumatoid Arthritis . . . ”,Clin Exp Innumol101:398-407 (1995).
Rollins, “Chemokines”,Blood, vol. 90 No. 3, pp. 909-928, Aug. 1, 1997.
Rousseau, Jean-Francois et al., Chemical Abstract, “Regioselective ortho-directed metalation and electrophilic substitution of indoleand indoling -5-(N-phenyl) carboxamides” retrieved from STN database
Anuskiewicz Steven E.
Inagaki Hideaki
Ishiwata Yoshiro
Jomori Takahito
Kakigami Takuji
Foley & Lardner LLP
Huang Evelyn Mei
Telik, Inc.
LandOfFree
Antagonists of MCP-1 function and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antagonists of MCP-1 function and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antagonists of MCP-1 function and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3527520